X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LNS8801 is an oral specific and potent agonist of GPER whose activity is dependent on the expression of GPER. GPER activation depletes c-Myc protein levels rapidly and durably. LNS8801 displays potent antitumor activities and inducing immune memory.
Lead Product(s): LNS8801
Therapeutic Area: Oncology Product Name: LNS8801
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
LNS8801 is an orally bioavailable and highly specific and potent agonist of GPER whose activity is dependent on the expression of GPER. In preclinical cancer models, LNS8801 displays potent antitumor activities across a wide range of tumor types.
Lead Product(s): LNS8801,Pembrolizumab
Therapeutic Area: Oncology Product Name: LNS8801
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The combination of LNS8801 with pembrolizumab has demonstrated strong signals of activity in patients with metastatic cancer who had previously benefited from and then developed secondary resistance to ICI therapy.
Lead Product(s): LNS8801,Pembrolizumab
Therapeutic Area: Oncology Product Name: LNS8801
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
LNS8801 is an orally bioavailable and highly specific and potent agonist of GPER whose activity is dependent on the expression of GPER. GPER activation by LNS8801 rapidly and durably depletes c-Myc protein levels.
Lead Product(s): LNS8801,Pembrolizumab
Therapeutic Area: Oncology Product Name: LNS8801
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
For the first time, any company has dosed a patient in a clinical trial specifically targeting the G protein-coupled estrogen receptor, in combination with pembrolizumab. LNS8801 is an orally bioavailable small molecule that is a highly specific and potent agonist of the GPER.
Lead Product(s): LNS8801,Pembrolizumab
Therapeutic Area: Oncology Product Name: LNS8801
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Collaboration agreement aims to study the combination of Linnaeus's lead investigational drug candidate LNS8801, and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors.
Lead Product(s): LNS8801,Pembrolizumab
Therapeutic Area: Oncology Product Name: LNS8801
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 23, 2020
Details:
U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or after anti–programmed cell death receptor or ligand (anti–PD-1/L1) therapy.
Lead Product(s): LNS8801
Therapeutic Area: Oncology Product Name: LNS8801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
The authors also demonstrated that GPER protein can be detected in a large percentage of clinical specimens, suggesting that GPER may represent a new therapeutic target for PDAC.
Lead Product(s): LNS8801
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
